Retraction: NK cell heparanase controls tumor invasion and immune surveillance (J Clin Invest. (2017) 127: 7 (2777–2788) DOI: 10.1172/JCI92958);NK cell heparanase controls tumor invasion and immune surveillance

Journal of Clinical Investigation

Volumn 127, Issue 7, 2017, Pages 2777-2788

  Putz, Eva M ^a   Mayfosh, Alyce J ^b   Kos, Kevin ^a   Barkauskas, Deborah S ^a   Nakamura, Kyohei ^a   Town, Liam ^a   Goodall, Katharine J ^b   Yee, Dean Y ^c   Poon, Ivan K H ^b   Baschuk, Nikola ^b   Souza Fonseca Guimaraes, Fernando ^a,d,e,f   Hulett, Mark D ^b   Smyth, Mark J ^a,d  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

^c Australian National University   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; CYTOKINE; HEPARANASE; NATURAL KILLER CELL RECEPTOR NKG2D; HEPARIN LYASE; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; NUCLEAR MATRIX PROTEIN; NUCLEOCYTOPLASMIC TRANSPORT PROTEIN; RAE1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER IMMUNOTHERAPY; CANCER SUSCEPTIBILITY; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; LYMPHOCYTE PROLIFERATION; LYMPHOMA CELL LINE; METASTATIC MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR INVASION; ANIMAL; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MALE; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CYTOKINES; FEMALE; HEPARIN LYASE; HUMANS; IMMUNOLOGIC SURVEILLANCE; KILLER CELLS, NATURAL; MALE; MICE; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; NUCLEAR MATRIX-ASSOCIATED PROTEINS; NUCLEOCYTOPLASMIC TRANSPORT PROTEINS;

EID: 85021709800     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI183295     Document Type: Erratum

References (65)

1. Halama N, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res. 2011;17(4):678-689.
2. Cantoni C, et al. NK cells, tumor cell transition, and tumor progression in solid malignancies: New hints for NK-based immunotherapy? J Immunol Res. 2016;2016:4684268.
3. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298-306.
4. Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol. 2011;3(7):a004952.
5. Zcharia E, et al. Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS ONE. 2009;4(4):e5181.
6. Poon IK, et al. Mice deficient in heparanase exhibit impaired dendritic cell migration and reduced airway inflammation. Eur J Immunol. 2014;44(4):1016-1030.
7. Abboud-Jarrous G, et al. Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem. 2008;283(26):18167-18176.
8. Cui H, et al. Heparanase expression upregulates platelet adhesion activity and thrombogenicity. Oncotarget. 2016;7(26):39486-39496.
9. Fux L, Ilan N, Sanderson RD, Vlodavsky I. Heparanase: busy at the cell surface. Trends Biochem Sci. 2009;34(10):511-519.
10. Sanderson RD, Elkin M, Rapraeger AC, Ilan N, Vlodavsky I. Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy. FEBS J. 2017;284(1):42-55.
11. Goldshmidt O, et al. Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J. 2003;17(9):1015-1025.
12. Gilat D, et al. Molecular behavior adapts to context: heparanase functions as an extracellular matrix-degrading enzyme or as a T cell adhesion molecule, depending on the local pH. J Exp Med. 1995;181(5):1929-1934.
13. Fux L, et al. Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res. 2009;69(5):1758-1767.
14. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med. 1999;5(7):803-809.
15. Vlodavsky I, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med. 1999;5(7):793-802.
16. Hammond E, Khurana A, Shridhar V, Dredge K. The role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumor microenvironment and opportunities for novel cancer therapeutics. Front Oncol. 2014;4:195.
17. Ostrovsky O, et al. Modification of heparanase gene expression in response to conditioning and LPS treatment: strong correlation to rs4693608 SNP. J Leukoc Biol. 2014;95(4):677-688.
18. Benhamron S, et al. Dissociation between mature phenotype and impaired transmigration in dendritic cells from heparanase-deficient mice. PLoS ONE. 2012;7(5):e35602.
19. Morris A, et al. The role of heparanase in pulmonary cell recruitment in response to an allergic but not non-allergic stimulus. PLoS ONE. 2015;10(6):e0127032.
20. Stoler-Barak L, et al. Heparanase of murine effector lymphocytes and neutrophils is not required for their diapedesis into sites of inflammation. FASEB J. 2015;29(5):2010-2021.
21. Caruana I, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21(5):524-529.
22. Benhamron S, et al. Translocation of active heparanase to cell surface regulates degradation of extracellular matrix heparan sulfate upon transmigration of mature monocyte-derived dendritic cells. J Immunol. 2006;176(11):6417-6424.
23. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol. 2001;13(4):459-463.
24. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001;413(6852):165-171.
25. Hayakawa Y, et al. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol. 2002;169(10):5377-5381.
26. Blake SJ, et al. Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer Discov. 2016;6(4):446-459.
27. de Andrade LF, Ngiow SF, Martinet L, Smyth MJ. Natural Killer cell control of BRAF(V600E) mutant melanoma during targeted therapy. Oncoimmunology. 2015;4(4):e998119.
28. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta. 2001;1471(3):M99-M108.
29. Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17(9):1025-1036.
30. Levy EM, Roberti MP, Mordoh J. Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol. 2011;2011:676198.
31. Wennerberg E, Kremer V, Childs R, Lundqvist A. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. Cancer Immunol Immunother. 2015;64(2):225-235.
32. Melero I, Rouzaut A, Motz GT, Coukos G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov. 2014;4(5):522-526.
33. Coca S, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997;79(12):2320-2328.
34. Ishigami S, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 2000;88(3):577-583.
35. Pasero C, et al. Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer. Oncotarget. 2015;6(16):14360-14373.
36. Qin Z, Kim HJ, Hemme J, Blankenstein T. Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction. J Exp Med. 2002;195(11):1479-1490.
37. Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res. 2008;68(20):8437-8445.
38. Riaz A, Ilan N, Vlodavsky I, Li JP, Johansson S. Characterization of heparanase-induced phosphatidylinositol 3-kinase-AKT activation and its integrin dependence. J Biol Chem. 2013;288(17):12366-12375.
39. Gingis-Velitski S, Zetser A, Flugelman MY, Vlodavsky I, Ilan N. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem. 2004;279(22):23536-23541.
40. Parish CR, et al. Unexpected new roles for heparanase in Type 1 diabetes and immune gene regulation. Matrix Biol. 2013;32(5):228-233.
41. He YQ, et al. The endoglycosidase heparanase enters the nucleus of T lymphocytes and modulates H3 methylation at actively transcribed genes via the interplay with key chromatin modifying enzymes. Transcription. 2012;3(3):130-145.
42. Purushothaman A, Hurst DR, Pisano C, Mizumoto S, Sugahara K, Sanderson RD. Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J Biol Chem. 2011;286(35):30377-30383.
43. Goodall KJ, Poon IK, Phipps S, Hulett MD. Soluble heparan sulfate fragments generated by heparanase trigger the release of pro-inflammatory cytokines through TLR-4. PLoS ONE. 2014;9(10):e109596.
44. Gutter-Kapon L, et al. Heparanase is required for activation and function of macrophages. Proc Natl Acad Sci USA. 2016;113(48):E7808-E7817.
45. Brennan TV, et al. Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation. J Clin Invest. 2016;126(1):207-219.
46. Rivara S, Milazzo FM, Giannini G. Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases. Future Med Chem. 2016;8(6):647-680.
47. Goldberg R, et al. Versatile role of heparanase in inflammation. Matrix Biol. 2013;32(5):234-240.
48. Vlodavsky I, Blich M, Li JP, Sanderson RD, Ilan N. Involvement of heparanase in atherosclerosis and other vessel wall pathologies. Matrix Biol. 2013;32(5):241-251.
49. Lisnić B, Lisnić VJ, Jonjić S. NK cell interplay with cytomegaloviruses. Curr Opin Virol. 2015;15:9-18.
50. Della Chiesa M, Marcenaro E, Sivori S, Carlomagno S, Pesce S, Moretta A. Human NK cell response to pathogens. Semin Immunol. 2014;26(2):152-160.
51. Dredge K, et al. PG545, a dual heparanase and angiogenesis inhibitor, induces potent antitumour and anti-metastatic efficacy in preclinical models. Br J Cancer. 2011;104(4):635-642.
52. Weissmann M, et al. Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis. Proc Natl Acad Sci U S A. 2016;113(3):704-709.
53. Ramani VC, et al. Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget. 2016;7(2):1598-1607.
54. Warren HS, Rana PM. An economical adaptation of the RosetteSep procedure for NK cell enrichment from whole blood, and its use with liquid nitrogen stored peripheral blood mononuclear cells. J Immunol Methods. 2003;280(1-2):135-138.
55. Warren HS, Kinnear BF, Witt CS, Christiansen FT. Proliferation of alloreactive human natural killer cells independent of specific allogeneic stimulation. Int Immunol. 1994;6(4):507-513.
56. Narni-Mancinelli E, et al. Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor. Proc Natl Acad Sci U S A. 2011;108(45):18324-18329.
57. DiSanto JP, Müller W, Guy-Grand D, Fischer A, Rajewsky K. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc Natl Acad Sci U S A. 1995;92(2):377-381.
58. Shinkai Y, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 1992;68(5):855-867.
59. Liu J, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6(12):1382-1399.
60. Ferrari de Andrade L, et al. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res. 2014;74(24):7298-7308.
61. Hayakawa Y, Andrews DM, Smyth MJ. Subset analysis of human and mouse mature NK cells. Methods Mol Biol. 2010;612:27-38.
62. de Mestre AM, Khachigian LM, Santiago FS, Staykova MA, Hulett MD. Regulation of inducible heparanase gene transcription in activated T cells by early growth response 1. J Biol Chem. 2003;278(50):50377-50385.
63. Poon IK, et al. Histidine-rich glycoprotein binds heparanase and regulates its enzymatic activity and cell surface interactions. Int J Biochem Cell Biol. 2010;42(9):1507-1516.
64. Freeman C, Parish CR. A rapid quantitative assay for the detection of mammalian heparanase activity. Biochem J. 1997;325 (Pt 1):229-237.
65. Vlodavsky I. Preparation of extracellular matrices produced by cultured corneal endothelial and PF-HR9 endodermal cells. Curr Protoc Cell Biol. 2001;Chapter 10:Unit 10.4.